Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study.
Hidetoshi KawaguchiYutaka YamamotoShigehira SajiNorikazu MasudaTakahiro NakayamaKenjiro AogiKeisei AnanYoshinori ItoShoichiro OhtaniNobuaki SatoToshimi TakanoEriko TokunagaSeigo NakamuraYoshie HasegawaMasaya HattoriTomomi FujisawaSatoshi MoritaMiki YamaguchiHiroko YamashitaToshinari YamashitaDaisuke YotsumotoMasakazu ToiShinji OhnoPublished in: Japanese journal of clinical oncology (2022)
The results of this study indicate that sequential endocrine monotherapy may be a useful treatment option for patients with estrogen receptor-positive/human epidermal growth factor receptor 2 negative recurrent breast cancer who have been successfully treated with initial long-term palliative endocrine therapy.